MA38406A1 - Virus de la maladie de newcastle et leurs utilisations - Google Patents

Virus de la maladie de newcastle et leurs utilisations

Info

Publication number
MA38406A1
MA38406A1 MA38406A MA38406A MA38406A1 MA 38406 A1 MA38406 A1 MA 38406A1 MA 38406 A MA38406 A MA 38406A MA 38406 A MA38406 A MA 38406A MA 38406 A1 MA38406 A1 MA 38406A1
Authority
MA
Morocco
Prior art keywords
newcastle disease
immune cell
viruses
disease virus
compositions
Prior art date
Application number
MA38406A
Other languages
English (en)
Other versions
MA38406B1 (fr
Inventor
Peter Palese
Sastre Adolfo Garcia
Dmitriy Zamarin
James Allison
Jedd D Wolchok
Original Assignee
Icahn School Med Mount Sinai
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai, Memorial Sloan Kettering Cancer Center filed Critical Icahn School Med Mount Sinai
Publication of MA38406A1 publication Critical patent/MA38406A1/fr
Publication of MA38406B1 publication Critical patent/MA38406B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des virus chimériques de la maladie de newcastle génétiquement modifiés pour exprimer un agoniste d'un signal de costimulation d'une cellule immunitaire et des compositions comprenant de tels virus. L'invention concerne également un virus chimérique de la maladie de newcastle génétiquement modifié pour exprimer un antagoniste d'un signal inhibiteur d'une cellule immunitaire et des compositions comprenant de tels virus. Les virus chimériques de la maladie de newcastle et les compositions sont utiles dans le traitement du cancer. De plus, l'invention concerne des méthodes de traitement du cancer comprenant l'administration de virus de la maladie de newcastle en combinaison avec un agoniste d'un signal de costimulation d'une cellule immunitaire et/ou un antagoniste d'un signal inhibiteur d'une cellule immunitaire.
MA38406A 2013-03-14 2014-03-04 Virus de la maladie de newcastle et leurs utilisations MA38406B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782994P 2013-03-14 2013-03-14
PCT/US2014/020299 WO2014158811A1 (fr) 2013-03-14 2014-03-04 Virus de la maladie de newcastle et leurs utilisations

Publications (2)

Publication Number Publication Date
MA38406A1 true MA38406A1 (fr) 2017-12-29
MA38406B1 MA38406B1 (fr) 2020-03-31

Family

ID=51527979

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38406A MA38406B1 (fr) 2013-03-14 2014-03-04 Virus de la maladie de newcastle et leurs utilisations

Country Status (28)

Country Link
US (5) US20160015760A1 (fr)
EP (1) EP2968525A4 (fr)
JP (4) JP6596411B2 (fr)
KR (1) KR102222157B1 (fr)
CN (3) CN111218429A (fr)
AP (1) AP2015008685A0 (fr)
AU (2) AU2014241843B2 (fr)
BR (1) BR112015021414B1 (fr)
CA (1) CA2905272A1 (fr)
CL (2) CL2015002532A1 (fr)
CR (1) CR20150465A (fr)
DO (1) DOP2015000227A (fr)
EA (1) EA038981B1 (fr)
GE (1) GEP20196976B (fr)
HK (1) HK1216618A1 (fr)
IL (2) IL241120A0 (fr)
MA (1) MA38406B1 (fr)
MD (1) MD4655C1 (fr)
MX (2) MX2015011886A (fr)
MY (1) MY180687A (fr)
NI (1) NI201500131A (fr)
NZ (1) NZ711946A (fr)
PE (1) PE20151921A1 (fr)
PH (1) PH12015502087A1 (fr)
SG (2) SG10201802982WA (fr)
TN (1) TN2015000353A1 (fr)
WO (1) WO2014158811A1 (fr)
ZA (1) ZA201506192B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2251034T (pt) 2005-12-02 2018-05-22 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
WO2010091262A1 (fr) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Virus chimériques de la maladie de newcastle et leurs utilisations
BR112015021414B1 (pt) * 2013-03-14 2020-11-10 Icahn School Of Medicine At Mount Sinai vírus da doença newcastle e seus usos
KR102310692B1 (ko) * 2013-09-03 2021-10-12 메디뮨 리미티드 약독화된 뉴캐슬병 바이러스를 특징으로 하는 조성물 및 신생물을 치료하기 위한 사용 방법
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
WO2015127501A1 (fr) 2014-02-27 2015-09-03 Viralytics Limited Thérapie combinée pour le traitement du cancer
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
NZ747418A (en) 2014-03-12 2023-05-26 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
CN112481283A (zh) 2014-07-21 2021-03-12 诺华股份有限公司 使用cd33嵌合抗原受体治疗癌症
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
EP3174546B1 (fr) 2014-07-31 2019-10-30 Novartis AG Sous-ensemble optimisé de lymphocytes t contenant un récepteur d'antigène chimère
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (fr) 2014-10-14 2023-12-13 Novartis AG Molécules d'anticorps de pd-l1 et leurs utilisations
EP3209382B1 (fr) * 2014-10-24 2020-11-25 Calidi Biotherapeutics, Inc. Technique d'immunotherapie combinee pour le traitement du cancer
WO2016090034A2 (fr) 2014-12-03 2016-06-09 Novartis Ag Méthodes de pré-conditionnement de cellules b dans une thérapie car
CN105985966A (zh) * 2015-03-06 2016-10-05 普莱柯生物工程股份有限公司 基因vii型新城疫病毒株、其疫苗组合物、制备方法及应用
SI3280729T1 (sl) 2015-04-08 2022-09-30 Novartis Ag Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
WO2017009842A2 (fr) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions et méthodes pour le traitement du cancer
EP3328418A1 (fr) 2015-07-29 2018-06-06 Novartis AG Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
KR102201147B1 (ko) 2015-08-11 2021-01-11 카리디 바이오테라퓨틱스, 인크. 암 치료에 사용하기 위한 천연두 백신
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
US10570377B2 (en) 2016-01-08 2020-02-25 Replimune Limited Oncolytic virus strain
WO2017149515A1 (fr) 2016-03-04 2017-09-08 Novartis Ag Cellules exprimant de multiples molécules de récepteur d'antigène chimère (car) et leurs utilisations
CN109641947B (zh) 2016-07-20 2023-04-14 犹他大学研究基金会 Cd229 car t细胞及其使用方法
TW202340473A (zh) 2016-10-07 2023-10-16 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
WO2018201051A1 (fr) 2017-04-28 2018-11-01 Novartis Ag Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
WO2018201056A1 (fr) 2017-04-28 2018-11-01 Novartis Ag Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
JOP20190256A1 (ar) * 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
JP2020521447A (ja) 2017-05-25 2020-07-27 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
KR20210020932A (ko) 2018-06-13 2021-02-24 노파르티스 아게 Bcma 키메라 항원 수용체 및 이의 용도
WO2020047328A1 (fr) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Thérapies combinées comprenant des protéines chimériques à base de pd -1
US20220047633A1 (en) 2018-09-28 2022-02-17 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
JP7398680B2 (ja) * 2018-10-09 2023-12-15 バイオコモ株式会社 抗がん剤、がん治療用医薬組成物、及びキット
CN109627336A (zh) * 2018-12-20 2019-04-16 南京昂科利医药科技创新研究院有限公司 一种表达pd-l1单链抗体的新城疫溶瘤病毒的制备方法及应用
US20230193213A1 (en) * 2019-01-29 2023-06-22 Arno Thaller Recombinant oncolytic newcastle disease viruses with increased activity
EP3938396A1 (fr) 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anticorps anti-icos pour le traitement du cancer
MX2021011608A (es) 2019-03-29 2021-12-10 Myst Therapeutics Llc Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
EP3725370A1 (fr) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Anticorps anti-pd-l1 modifiés et procédés et utilisations pour le traitement d'une maladie neurodégénérative
CN110564766A (zh) * 2019-09-20 2019-12-13 华农（肇庆）生物产业技术研究院有限公司 一种全基因组表达载体pBR322-DHN3的制备方法
CN110672844A (zh) * 2019-10-29 2020-01-10 华中科技大学 一种新城疫病毒抗体磁免疫化学发光检测试剂盒及其应用
WO2021091960A1 (fr) 2019-11-05 2021-05-14 Jounce Therapeutics, Inc. Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors cd19 and cd22 and their uses
CN115023270A (zh) 2019-11-27 2022-09-06 迈斯特治疗公司 使用调节剂产生肿瘤反应性t细胞组合物的方法
CN115427438A (zh) 2020-02-27 2022-12-02 迈斯特治疗公司 肿瘤反应性t细胞的离体富集和扩增的方法及其相关组合物
US20210386804A1 (en) * 2020-06-11 2021-12-16 Tibor Bakács Combination of viral superinfection therapy with subthreshold doses of nivolumab plus ipilimumab in chronic HBV patients
CA3198447A1 (fr) 2020-11-13 2022-05-19 Novartis Ag Polytherapies avec des cellules exprimant un recepteur antigenique chimerique (car)
CN115197949A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途
TW202307210A (zh) 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
KR102476901B1 (ko) * 2021-08-06 2022-12-14 리벤텍 주식회사 대장암 세포 특이적 감염 뉴캐슬병 바이러스를 이용한 대장암 치료용 암용해성 바이러스 및 이를 이용한 대장암 치료용 조성물

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
DE3922444A1 (de) 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
DK1314431T3 (da) 1993-04-30 2008-11-10 Wellstat Biologics Corp Oprensede sammensætninger af Newcastle disease virus
ATE257175T1 (de) 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
JPH11512609A (ja) 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産
WO1997014433A1 (fr) 1995-10-17 1997-04-24 Wayne State University Interleukine-15 du poulet et ses utilisations
EP2112220A3 (fr) 1996-07-15 2010-01-06 The Government of the United States of America, as represented by The Department of Health and Human Services Production de vaccins contre le virus respiratoire syncytial atténué à partir de séquences nucléotides clonées
AU4427897A (en) 1996-09-27 1998-04-17 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
AU7797798A (en) 1997-05-23 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
PT1012244E (pt) 1997-07-11 2007-08-21 Univ Yale ''rabdovírus com revestimentos remanipulados''
CN1273603A (zh) 1997-09-19 2000-11-15 美国氰胺公司 减毒的呼吸道合胞病毒
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
NZ518945A (en) 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US6573079B1 (en) 1998-06-12 2003-06-03 Mount Sinai School Of Medicine Of New York University Methods and interferon deficient substrates for the propagation of viruses
EP0974660A1 (fr) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Clones infectieux du virus de la maladie de Newcastle, vaccins et analyses diagnostiqués
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US7052685B1 (en) 1998-10-15 2006-05-30 Trustees Of The University Of Pennsylvania Methods for treatment of cutaneous T-cell lymphoma
EP1390046A4 (fr) 1999-04-15 2005-04-20 Wellstat Biologics Corp Traitement de neoplasmes avec des virus
WO2000067786A1 (fr) 1999-05-05 2000-11-16 University Of Maryland Production de nouvelles souches de virus de la maladie de newcastle a partir d'adn complementaires et vaccins vivants attenues ameliores contre la maladie de newcastle
US20030224017A1 (en) 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
ATE353370T1 (de) 1999-07-14 2007-02-15 Sinai School Medicine In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
WO2001020989A1 (fr) 1999-09-22 2001-03-29 Mayo Foundation For Medical Education And Research Procedes et compositions therapeutiques utilisant des virus de la famille paramyxoviridae de recombinaison
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
WO2001052874A2 (fr) 2000-01-20 2001-07-26 Universität Zürich Institut für Medizinische Virologie Administration intra-tumorale de molecules d'acides nucleiques codant pour il-12
WO2001077394A1 (fr) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Methodes de criblage destinees a l'identification de proteines virales au moyen de fonctions antagonistes d'interferons et d'agents antiviraux potentiels
US6818444B2 (en) 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
WO2002102404A1 (fr) 2001-06-18 2002-12-27 Institut National De La Recherche Agronomique Utilisations de cytokines
AU2003223089A1 (en) 2002-04-29 2003-11-17 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
CA2488270A1 (fr) 2002-06-03 2003-12-11 Dnavec Research Inc. Vecteurs de paramyxovirus codant pour des anticorps et utilisations connexes
WO2004015572A1 (fr) 2002-08-07 2004-02-19 Mmagix Technology Limited Appareil, procede et systeme destines a un processeur independant de la synchronicite, capable d'optimiser l'energie et les instructions et de deleguer les ressources
SE0203159D0 (sv) 2002-10-25 2002-10-25 Electrolux Ab Handtag till ett motordrivet handhållet verktyg
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
JP5744369B2 (ja) 2004-02-27 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
CN101056646A (zh) 2004-11-12 2007-10-17 拜耳先灵医药股份有限公司 重组新城疫病毒
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
WO2007008918A2 (fr) 2005-07-08 2007-01-18 Wayne State University Vaccins de virus comprenant des proteines immunomodulatrices reliees a une enveloppe, et methode d'utilisation associee
EP1777294A1 (fr) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion
PT2251034T (pt) 2005-12-02 2018-05-22 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
NZ569541A (en) 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
CA2647282A1 (fr) 2006-04-05 2007-10-11 Pfizer Products Inc. Polytherapie a base d'un anticorps anti-ctla4
US20090175826A1 (en) 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
US20110044937A1 (en) 2006-07-27 2011-02-24 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
EP3293266A1 (fr) 2007-05-04 2018-03-14 University Health Network Immunothérapie par il-12 pour le cancer
CN108948177B (zh) 2007-05-11 2022-04-22 阿尔托生物科学有限公司 融合分子与il-15变异体
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
ES2466916T3 (es) 2007-06-27 2014-06-11 Admune Therapeutics Llc Complejos de IL-15 e IL-15R alfa y usos de los mismos
EP2085092A1 (fr) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Paramyxovirus oncolytiques atténués encodant des cytokines aviaires
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
RS54233B1 (en) 2008-08-25 2015-12-31 Amplimmune Inc. PD-1 ANTAGONIST COMPOSITIONS AND PROCEDURES FOR THEIR APPLICATION
WO2010042433A1 (fr) * 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
CN101787373B (zh) 2009-01-23 2013-06-19 中国人民解放军第二军医大学东方肝胆外科医院 一种携带外源基因在包装细胞中高效生产的重组病毒载体、其构建方法及其用途
WO2010091262A1 (fr) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Virus chimériques de la maladie de newcastle et leurs utilisations
AU2010241864B2 (en) 2009-04-30 2014-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
AU2010282280B2 (en) 2009-08-14 2016-06-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 to increase thymic output and to treat lymphopenia
RU2592544C2 (ru) 2009-08-21 2016-07-20 Мериал, Инк. Способ получения рекомбинантного вирусного вектора apmv-8
EP3375791A1 (fr) 2009-09-30 2018-09-19 Memorial Sloan Kettering Cancer Center Immunothérapie combinée pour le traitement du cancer
WO2011119628A2 (fr) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions et méthodes de préparation de vaccins auto-adjuvants contre microbes et tumeurs
WO2012000188A1 (fr) 2010-06-30 2012-01-05 Tot Shanghai Rd Center Co., Ltd. Vaccin recombinant antitumoral et son procédé de production
ES2651170T3 (es) 2010-09-21 2018-01-24 Altor Bioscience Corporation Moléculas de fusión solubles multímeras de IL-15 y métodos para elaborar y usar las mismas
US20120082687A1 (en) * 2010-10-04 2012-04-05 Alex Wah Hin Yeung Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use
EA201301173A1 (ru) 2011-04-15 2015-08-31 Дженелюкс Корпорейшн Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
EP2537933A1 (fr) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
ES2671728T3 (es) 2011-10-11 2018-06-08 Universität Zürich Prorektorat Mnw Medicamento de combinación que comprende IL-12 y un agente para el bloqueo de moléculas inhibidoras de linfocitos T para terapia tumoral
KR102081567B1 (ko) 2012-01-25 2020-02-26 디엔에이트릭스, 인코포레이티드 바이오마커 및 종양분해 바이러스 및 면역 조절을 사용한 병용 치료요법
EP2669381A1 (fr) 2012-05-30 2013-12-04 AmVac AG Procédé pour l'expression de protéines hétérologues à l'aide d'un vecteur de virus recombinant à ARN négatifs comprenant une P proteine mutante
WO2014047350A1 (fr) 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Virus oncolytique codant pour des agents de liaison de pd-1 et ses utilisations
US20150359853A1 (en) 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
BR112015021414B1 (pt) 2013-03-14 2020-11-10 Icahn School Of Medicine At Mount Sinai vírus da doença newcastle e seus usos
DK2986312T3 (da) 2013-04-19 2022-02-14 Cytune Pharma Cytokinafledt behandling med reduceret vaskulært lækagesyndrom
EP3030575B1 (fr) 2013-08-08 2018-07-11 Cytune Pharma Modulokines basées sur l'il-15 et le domaine sushi de il-15r-alpha
PT3030262T (pt) 2013-08-08 2019-12-11 Inst Gustave Roussy Igr Composição farmacêutica de associação
KR102310692B1 (ko) 2013-09-03 2021-10-12 메디뮨 리미티드 약독화된 뉴캐슬병 바이러스를 특징으로 하는 조성물 및 신생물을 치료하기 위한 사용 방법
WO2015127501A1 (fr) 2014-02-27 2015-09-03 Viralytics Limited Thérapie combinée pour le traitement du cancer
EP2915569A1 (fr) 2014-03-03 2015-09-09 Cytune Pharma Procédé de purification de conjugués à base Il -15/IL-15Ralpha
ES2811974T3 (es) 2014-07-29 2021-03-15 Novartis Ag Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones
US20170291934A1 (en) 2014-09-22 2017-10-12 Charles C. Reed Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
AU2015360736A1 (en) 2014-12-09 2017-06-01 Merck Sharp & Dohme Corp. System and methods for deriving gene signature biomarkers of response to PD-1 antagonists
CN106166294A (zh) 2015-05-18 2016-11-30 国科丹蓝生物科技（北京）有限公司 一种用于术前介入放疗治疗肿瘤的化合物
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
EP3328418A1 (fr) 2015-07-29 2018-06-06 Novartis AG Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CA3001590A1 (fr) 2015-10-10 2017-04-13 Intrexon Corporation Controle therapeutique ameliore de formes d'interleukine-12 destabilisees sensibles a la proteolyse
ES2785503T3 (es) 2015-11-09 2020-10-07 Immune Design Corp Composiciones que comprenden vectores lentivíricos que expresan IL-12 y métodos de uso de los mismos
US10570377B2 (en) 2016-01-08 2020-02-25 Replimune Limited Oncolytic virus strain
US11612426B2 (en) 2016-01-15 2023-03-28 Immunsys, Inc. Immunologic treatment of cancer
US10344067B2 (en) 2016-02-25 2019-07-09 Deutsches Krebsforschungszentrum RNA viruses expressing IL-12 for immunovirotherapy
CN105734023B (zh) 2016-03-28 2019-04-26 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒在制备抗肝癌药物中的应用
US20190106709A1 (en) 2016-04-29 2019-04-11 Virogin Biotech Canada Ltd Hsv vectors with enhanced replication in cancer cells

Also Published As

Publication number Publication date
CR20150465A (es) 2016-01-25
EA038981B1 (ru) 2021-11-17
BR112015021414A2 (pt) 2017-07-18
EP2968525A1 (fr) 2016-01-20
BR112015021414B1 (pt) 2020-11-10
US10251922B2 (en) 2019-04-09
US20140271677A1 (en) 2014-09-18
CL2018000515A1 (es) 2018-08-03
NZ711946A (en) 2020-05-29
US20180256655A1 (en) 2018-09-13
WO2014158811A8 (fr) 2015-09-17
IL241120A0 (en) 2015-11-30
IL264385B (en) 2021-09-30
MD4655C1 (ro) 2020-06-30
CL2015002532A1 (es) 2016-07-15
US20180078592A1 (en) 2018-03-22
WO2014158811A1 (fr) 2014-10-02
GEP20196976B (en) 2019-06-10
MY180687A (en) 2020-12-07
PE20151921A1 (es) 2015-12-26
JP2020202850A (ja) 2020-12-24
SG10201802982WA (en) 2018-06-28
CN111172120A (zh) 2020-05-19
PH12015502087B1 (en) 2016-01-18
ZA201506192B (en) 2021-01-27
AU2014241843A1 (en) 2015-09-10
JP6596411B2 (ja) 2019-10-23
NI201500131A (es) 2015-10-19
TN2015000353A1 (en) 2017-01-03
CA2905272A1 (fr) 2014-10-02
MD20150100A2 (ro) 2016-02-29
AU2014241843B2 (en) 2019-05-02
MD4655B1 (ro) 2019-11-30
PH12015502087A1 (en) 2016-01-18
KR102222157B1 (ko) 2021-03-03
CN105188746A (zh) 2015-12-23
CN105188746B (zh) 2020-03-17
MA38406B1 (fr) 2020-03-31
AP2015008685A0 (en) 2015-08-31
HK1216618A1 (zh) 2016-11-25
AU2019206040A1 (en) 2019-08-01
SG11201507412SA (en) 2015-10-29
CN111218429A (zh) 2020-06-02
IL264385A (en) 2019-02-28
EA201591740A1 (ru) 2016-06-30
MX2019008086A (es) 2019-09-10
US20160015760A1 (en) 2016-01-21
DOP2015000227A (es) 2015-11-15
EP2968525A4 (fr) 2016-10-26
US20180280455A1 (en) 2018-10-04
MX2015011886A (es) 2016-05-31
JP2016517269A (ja) 2016-06-16
KR20150127164A (ko) 2015-11-16
JP2018198621A (ja) 2018-12-20
JP2023002553A (ja) 2023-01-10

Similar Documents

Publication Publication Date Title
MA38406A1 (fr) Virus de la maladie de newcastle et leurs utilisations
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201992350A1 (ru) Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
GEP20217328B (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MA35130B1 (fr) Composition comprenant de l'aflibercept, de l'acide folinique, du 5-fluoro-uracile (5-fu) et de l'irinocetan (folfiri)
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MA38814B2 (fr) Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
EA201391616A1 (ru) Применение тиазолидных соединений для предотвращения и лечения вирусных заболеваний, рака и заболеваний, вызванных внутриклеточными инфекциями
EA201400625A1 (ru) Антитела против pd-l1 и их применение
EA201590890A1 (ru) Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
MA37963A1 (fr) Protéines de fusion pour traiter un syndrome métabolique
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
GEP20217249B (en) Stable liquid pharmaceutical preparation
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
EA201690633A1 (ru) Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MA39390A1 (fr) Thérapie génique pour le traitement de la rétinite pigmentaire
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
MA40283A (fr) Aptamères spécifiques du récepteur tlr-4 et leurs utilisations